← Back
Menin2026-07-29

Menin Inhibitor Drug Development Landscape: Two AML Approvals and a Pipeline Eyeing Diabetes

Revumenib and ziftomenib became the first approved menin inhibitors, treating KMT2A-rearranged and NPM1-mutant acute myeloid leukemias. Here is what the rest of the menin-targeting pipeline looks like, from next-generation oncology combinations to an emerging frontier in diabetes.

Menin Drug Development Overview

The menin protein plays a critical, facilitative role in cell division and growth processes for a subset of leukemias. Targeting menin can inhibit its interaction with the KMT2A protein to disrupt a cancer cell's proliferation and instead drive it towards differentiation into a mature, non-cancerous cell.[1][2]

Menin inhibition is particularly relevant for acute myeloid leukemias (AML) and acute lymphoblastic leukemias (ALL) with KMT2A rearrangements and NPM1 mutations.[1] Roughly 80% of ALL patients have a KMT2A rearrangement, with another 30% of AML patients carrying KMT2A and NPM1 mutations.[3] Additional mutations have also been linked in the lab to menin-KMT2A dependence, including NUP98 translocation and UBTF tandem duplication. These subgroups may prove to be additional indications where menin therapies demonstrate clinical value.[2]

Menin has also demonstrated clinical relevance in a completely separate disease: diabetes. Since menin is believed to play a crucial role in beta-cell turnover and growth, its inhibition may lead to regeneration of normal beta cells and a return to regular insulin secretion in diabetes patients.[4] Additional disease areas beyond leukemia and diabetes where menin inhibition proves valuable may yet be discovered, given menin's role as an important scaffold protein in cells.

A single therapeutic strategy dominates the menin-targeting treatment landscape, which involves small molecule inhibitors that prevent menin-KMT2A interactions.[5] While the current landscape is focused on inhibition, future therapies in this space may target menin protein degradation to overcome the key limitation that first-generation inhibitors face: cancer cells start mutating their menin protein and the drug is no longer able to bind to it, rendering it much less effective.[6] There is however very little pipeline activity in the menin degrader space and programs are all in the discovery / preclinical stages, so any potential menin degrader is at least half a decade if not further out from potentially hitting the market.

Lastly, another unique approach for leveraging menin inhibitors in AML treatment is also emerging. Certain studies are exploring the use of menin inhibitors as a pretreatment to enhance CAR-T effects in AML; the menin blocker increases CLL-1 expression on cancer cells to enable CAR-T cells to better target and attack the cancerous cells.[7]

Approved Menin Inhibitors

To date, two menin-inhibitor therapies have been FDA approved:

  • revumenib (Revuforj): developed by Syndax Pharma, revumenib received initial FDA approval in November 2024 as an oral treatment for relapsed/refractory (r/r) acute leukemia in patients with a KMT2A translocations.[8] The label was later expanded to include r/r AML patients with NPM1 mutations in October 2025.[9] This was the first-in-class therapy for this market and is a traditional small molecule inhibitor.[10][11]
  • ziftomenib (Komzifti): developed by Kura Oncology, ziftomenib's approval came in November 2025 for r/r AML patients with NPM1 mutations and no other treatment options.[12] Ziftomenib is another small molecule menin inhibitor.[13]

The clinical efficacy is relatively similar between revumenib and ziftomenib, achieving complete remission in 21-23% of patients in their pivotal clinical trials.[8][9][12]

Pipeline Summary

Below is a summary of the clinical stage menin inhibitor drug development pipeline:

See more of our competitive intelligence research:

Non-Small Cell Lung Cancer (NSCLC)

Ivonescimab (SMT112) in NSCLC: Independent Peak Sales Estimate

Read report →In Vivo CAR-T

In Vivo CAR-T Landscape: T-cell Reprogramming Directly in Patients

Read report →

Explore our full library of competitive intelligence reports

Browse All Research

We build and maintain live versions of these therapeutic pipelines for teams tracking specific assets.

Take your competitive intelligence to the next level.

Book a Call